During the past decade, Tokyo Medical University Hachioji Medical Center conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 18 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 13 clinical trials were completed. i.e. 68.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Medical University Hachioji Medical Center" #1 sponsor was "Boehringer Ingelheim" with 8 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Pfizer" with 5 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Abbott Medical Devices" with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical University Hachioji Medical Center" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Japan Clinical Research Support Unit(J-CRSU)" with 1 trials as a collaborator and "Korean Cancer Study Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Medical University Hachioji Medical Center" are "Alzheimer Disease" (3 trials), "COVID-19" (3 trials), "Generalized Pustular Psoriasis" (3 trials), "Psoriasis" (3 trials) and "Covid19" (2 trials). Many other conditions were trialed in "Tokyo Medical University Hachioji Medical Center" in a lesser frequency.

Most popular intervention types in "Tokyo Medical University Hachioji Medical Center" are "Drug" (31 trials), "Procedure" (6 trials), "Other" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Sham Procedure" (7 trials), "Faricimab" (6 trials), "Aflibercept" (4 trials) and "Spesolimab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Medical University Hachioji Medical Center" are 34 trials for "All" genders.

Currently, there are NaN active trials in "Tokyo Medical University Hachioji Medical Center". undefined are not yet recruiting, 3 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Tokyo Medical University Hachioji Medical Center, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Medical University Hachioji Medical Center, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".